Therapeutic Research

Abstract

Objective：We had reported efficacy on fracture risk reduction of monthly intravenous ibandronate（ Ⅳ IBN） 1 mg in the MOVER study in Japanese osteoporotic patients. This post‒hoc analysis presents additional 3‒year data on bone mineral density （BMD） gains with respect to achieving the BMD T‒score target. Material and Methods：MOVER was a randomised, double‒blind study in ambulatory patients aged≧60 years with fragility fracture. 1265 patients received monthly Ⅳ IBN（0.5 mg, 1 mg）or oral risedronate（RIS）as active comparator. Results：The per‒protocol set comprised 1134 patients（IBN 1 mg n＝382, RIS n＝376）. Baseline patient characteristics were balanced across the groups. In patients with lumbar spine （LS） BMD T‒score≦－2.5 SD at baseline, the proportion of patients with LS BMD T‒score＞－2.5 SD was：27.0％ and 20.5％ after 1 year；34.6％ and 22.0％ after 2 years；and 42.2％ and 25.3％ after 3 years, with 1 mg IBN and RIS, respectively. The proportion of patients with LS BMD T‒score＞－2.5 SD increased with treatment duration in all treatment groups. These findings were consistent for proximal femur BMD gains：the proportion of patients with hip BMD T‒score＞－2.5 SD was：19.4％ and 16.8％ after 1 year；20.4％ and 19.2％ after 2 years；and 21.3％ and 15.2％ after 3 years, respectively. Conclusions：Monthly Ⅳ IBN 1 mg demonstrated the greatest BMD gains amongst treatments in the MOVER study. In the current analysis, Ⅳ IBN 1 mg also showed the greatest proportion of patients with LS BMD T‒score＞－2.5 SD. The proportion of patients achieving a BMD T‒score＞－2.5 SD increased with treatment duration. These findings suggest that treatment adherence is important for effective disease management with osteoporotic agents.